Share Twitter LinkedIn Facebook Email Robert A. Figlin, MD, explains the convenience factor of oral TKIs & treatment decisions in advanced RCC
Genitourinary Cancer [2025] Treatment Breakthroughs: ASCO GU 2025 Highlights Nataliya Mar, MD – MOASC Genitourinary 6 Mins Read
Tivozanib for RCC: Unpacking Efficacy, Safety, and Dose Optimization – Bradley McGregor, MD – Dana Farber Genitourinary 3 Mins Read
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read